Leniolisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.604
CATDS
0.017
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Leniolisib. Strongest target: AKT3 at 27.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | AKT3 | 27.4% | 72.6% |
| 2 | DAPK2 | 20.1% | 79.9% |
| 3 | SYK | 19.5% | 80.5% |
| 4 | STK33 | 19.2% | 80.8% |
| 5 | ALK4_ACVR1B | 18.6% | 81.4% |
| 6 | MAST3 | 18.0% | 82.0% |
| 7 | MEKK3 | 17.2% | 82.8% |
| 8 | WNK3 | 17.0% | 83.0% |
| 9 | CDC7_DBF4 | 15.8% | 84.2% |
| 10 | ERK1 | 15.8% | 84.2% |
| 11 | CDK1_CYCLIN_A | 15.7% | 84.3% |
| 12 | PDK3_PDHK3 | 15.7% | 84.3% |
| 13 | DNA_PK | 15.6% | 84.4% |
| 14 | EPHA6 | 15.3% | 84.7% |
| 15 | TYRO3_SKY | 15.2% | 84.8% |
| 16 | RAF1 | 15.2% | 84.8% |
| 17 | CDK6_CYCLIN_D3 | 14.3% | 85.7% |
| 18 | JNK2 | 13.5% | 86.5% |
| 19 | ERN1_IRE1 | 13.4% | 86.6% |
| 20 | PKG1B | 13.4% | 86.6% |
Selectivity landscape
Where Leniolisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Leniolisib.
Annotations
Sign in to read and post annotations.
Loading…